Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Development and validation of the mastocytosis activity score
|Filename||319. Siebenhaar et al., MAS, Allergy 2018.pdf|
|Date added||June 13, 2020|
|Tags||Disease activity, mastocytosis, Patient reported outcome, Questionnaire, symptoms|
|Authors||Siebenhaar, F., Sander, B., Ho, L. H. T., Ellrich, A., Maurer, M. and Weller, K.|
|Citation||Siebenhaar, F., Sander, B., Ho, L. H. T., Ellrich, A., Maurer, M. and Weller, K.: Development and validation of the mastocytosis activity score. Allergy 2018: 73; 1489-1496.|
|Corresponding authors||Siebenhaar, F.|
|Edition; Page||73; 1489-1496|
Background: Mastocytosis is a heterogeneous disease characterized by a clonal expansion of mast cells in various organs. The vast majority of patients suffer from signs and symptoms caused by mediator release from mast cells. Although the dis- ease burden is high, there is currently no specific and validated instrument to mea- sure and monitor signs and symptoms in patients with mastocytosis.
Objective: To develop and validate a disease-specific tool to measure and monitor the activity of signs and symptoms in patients with mastocytosis, the Mastocytosis Activity Score (MAS).
Methods: Nineteen potential MAS items were developed in a combined approach consisting of semi-structured patient interviews, expert input and literature research. Item selection was performed by impact analysis with 76 patients followed by a review for face validity. The resulting MAS was tested for validity, reliability and influence factors. In parallel, a US American English version of the MAS was devel- oped.
Results: A total of 68 mastocytosis patients took part in the MAS validation study. The final 9-item MAS was found to have a three-domain structure (“skin,” “gastroin- testinal tract” and “other”), a valid total score and an excellent test-retest reliability. Multiple regression analysis revealed that disease duration, age or gender is not a significant determinant of the MAS results.
Conclusions: The MAS is a disease-specific, valid and reliable patient-reported out- come measure for adult patients with cutaneous and indolent systemic mastocyto- sis. It may serve as a valuable tool to measure and monitor mastocytosis activity, both, in clinical trials and in routine care.
(Last update: 02.2021)
|Number of publications (original work and reviews) in peer-reviewed journals:||601|
|Number of original publications in peer-reviewed journals:||432|
|Number of reviews in peer-reviewed journals:||169|
|Cumulative IF of publications (original work & reviews) in peer-reviewed journals:||3326,21|
|Cumulative IF for original publications in peer-reviewed journals:||2659,47|
|Cumulative IF for reviews in peer-reviewed journals:||666,74|
|Citations, Hirsch index: (view on Web of Science)||24104|